ATE198149T1 - Verfahren zur stabilisierung von duocarmycinderivaten - Google Patents

Verfahren zur stabilisierung von duocarmycinderivaten

Info

Publication number
ATE198149T1
ATE198149T1 AT95918749T AT95918749T ATE198149T1 AT E198149 T1 ATE198149 T1 AT E198149T1 AT 95918749 T AT95918749 T AT 95918749T AT 95918749 T AT95918749 T AT 95918749T AT E198149 T1 ATE198149 T1 AT E198149T1
Authority
AT
Austria
Prior art keywords
pct
duocarmycin derivatives
stabilizing
sec
image
Prior art date
Application number
AT95918749T
Other languages
English (en)
Inventor
Masashi Nakakura
Yuji Ueno
Eiji Hayakawa
Tokuyuki Kuroda
Original Assignee
Kyowa Hakko Kogyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Kk filed Critical Kyowa Hakko Kogyo Kk
Application granted granted Critical
Publication of ATE198149T1 publication Critical patent/ATE198149T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Detergent Compositions (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AT95918749T 1994-05-20 1995-05-19 Verfahren zur stabilisierung von duocarmycinderivaten ATE198149T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP6106415A JPH07309761A (ja) 1994-05-20 1994-05-20 デュオカルマイシン誘導体の安定化法
PCT/JP1995/000962 WO1995031971A1 (en) 1994-05-20 1995-05-19 Method for stabilizing duocarmycin derivatives

Publications (1)

Publication Number Publication Date
ATE198149T1 true ATE198149T1 (de) 2001-01-15

Family

ID=14433044

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95918749T ATE198149T1 (de) 1994-05-20 1995-05-19 Verfahren zur stabilisierung von duocarmycinderivaten

Country Status (17)

Country Link
US (1) US5703080A (de)
EP (1) EP0754030B1 (de)
JP (1) JPH07309761A (de)
CN (1) CN1148805A (de)
AT (1) ATE198149T1 (de)
AU (1) AU2455195A (de)
BR (1) BR9507640A (de)
CA (1) CA2190635A1 (de)
CZ (1) CZ338696A3 (de)
DE (1) DE69519667T2 (de)
FI (1) FI964624L (de)
HU (1) HUT78072A (de)
NO (1) NO964813L (de)
NZ (1) NZ285450A (de)
PL (1) PL317229A1 (de)
SK (1) SK148496A3 (de)
WO (1) WO1995031971A1 (de)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2201097A1 (en) * 1994-09-30 1996-04-11 Kyowa Hakko Kogyo Co., Ltd. Anti-tumor agents
WO2002080987A1 (en) * 2001-04-09 2002-10-17 Progenics Pharmaceuticals, Inc. Anti-cd19 immunotoxins
US7129261B2 (en) 2001-05-31 2006-10-31 Medarex, Inc. Cytotoxic agents
ZA200507752B (en) * 2003-03-28 2007-01-31 Threshold Pharmaceuticals Inc Compositions and methods for treating cancer
RU2402548C2 (ru) 2004-05-19 2010-10-27 Медарекс, Инк. Химические линкеры и их конъюгаты
WO2005112919A2 (en) 2004-05-19 2005-12-01 Medarex, Inc. Self-immolative linkers and drug conjugates
SI1853718T1 (sl) 2005-02-15 2016-02-29 Duke University Protitelesa anti-CD19 in uporabe v onkologiji
US20060263357A1 (en) 2005-05-05 2006-11-23 Tedder Thomas F Anti-CD19 antibody therapy for autoimmune disease
US7714016B2 (en) 2005-04-08 2010-05-11 Medarex, Inc. Cytotoxic compounds and conjugates with cleavable substrates
CN102746336B (zh) 2005-06-29 2015-08-19 施瑞修德制药公司 氨基磷酸酯烷化剂前体药物
EP1940470B1 (de) 2005-09-26 2013-04-17 Medarex, Inc. Antikörper-Arzneimittel-Konjugate und deren Anwendung
EA015324B1 (ru) 2005-10-26 2011-06-30 Медарекс, Инк. Способы и соединения для получения аналогов сс-1065
CA2627190A1 (en) 2005-11-10 2007-05-24 Medarex, Inc. Duocarmycin derivatives as novel cytotoxic compounds and conjugates
EP2650306A1 (de) 2006-03-06 2013-10-16 Aeres Biomedical Limited Humanisierte Anti-CD22-Antikörper und ihre Verwendung bei der Behandlung von Krebs, Transplantationen und Autoimmunerkrankungen
BRPI0717902A2 (pt) 2006-12-01 2013-10-29 Medarex Inc "anticorpo monoclonal humano isolado, composição, conjugado anticorpo-molécula parceria, imunoconjugado, molécula de ácido nucléico isolada, vetor de expressão, célula hospedeira, método para prepar um anticorpo anti-cd22, método para inibir o desenvolvimento de uma célula tumoral que expressa cd22 e método para tratar uma doença inflamatória ou autoimuneem um indivíduo"
CL2007003622A1 (es) 2006-12-13 2009-08-07 Medarex Inc Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
JP2010513306A (ja) 2006-12-14 2010-04-30 メダレックス インコーポレーティッド Ｃｄ７０に結合するヒト抗体およびその使用
EP2114157B1 (de) * 2006-12-26 2021-05-26 ImmunoGenesis, Inc. Phosphoramidatalkylator-prodrug für die krebstherapie
TWI412367B (zh) 2006-12-28 2013-10-21 Medarex Llc 化學鏈接劑與可裂解基質以及其之綴合物
CA2678514A1 (en) 2007-02-21 2008-08-28 Medarex, Inc. Chemical linkers with single amino acids and conjugates thereof
JP5575636B2 (ja) 2007-05-07 2014-08-20 メディミューン，エルエルシー 抗ｉｃｏｓ抗体ならびに、腫瘍、移植および自己免疫疾患の治療におけるその使用
US9901567B2 (en) 2007-08-01 2018-02-27 Syntarga B.V. Substituted CC-1065 analogs and their conjugates
EP2185188B1 (de) 2007-08-22 2014-08-06 Medarex, L.L.C. Ortsspezifische bindung von wirkstoffen oder anderen mitteln an gentechnisch hergestellte antikörper mit c-terminalen erweiterungen
CA2700860C (en) 2007-10-01 2016-07-19 Jonathan A. Terrett Human antibodies that bind mesothelin, and uses thereof
EP2225275A4 (de) * 2007-11-28 2013-04-03 Medimmune Llc Proteinformulierung
KR20100101122A (ko) * 2007-11-30 2010-09-16 브리스톨-마이어스 스큅 컴퍼니 항-ｒｇ-１ 항체의 접합체
EP2344536A1 (de) 2008-09-19 2011-07-20 MedImmune, LLC Gegen dll4 gerichtete antikörper und anwendungen davon
CA2742568C (en) 2008-11-03 2017-09-26 Syntarga B.V. Novel cc-1065 analogs and their conjugates
BRPI0921845A2 (pt) 2008-11-12 2019-09-17 Medimmune Llc formulação aquosa estéril estável, forma de dosagem unitária farmacêutica, seringa pré-carregada, e, métodos para tratar uma doença ou distúrbio, para tratar ou prevenir rejeição, para esgotar células t que expressam icos em um paciente humano, e para interromper arquitetura central germinal em um órgão linfóide secundário de um primata
JP2012513194A (ja) 2008-12-23 2012-06-14 アストラゼネカ アクチボラグ α５β１に向けられた標的結合剤およびその使用
WO2011005481A1 (en) 2009-06-22 2011-01-13 Medimmune, Llc ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
US20120231004A1 (en) 2009-10-13 2012-09-13 Oxford Biotherapeutic Ltd. Antibodies
PT2504364T (pt) 2009-11-24 2017-11-14 Medimmune Ltd Agentes de ligação direcionados contra b7-h1
WO2011100403A1 (en) 2010-02-10 2011-08-18 Immunogen, Inc Cd20 antibodies and uses thereof
EP3108886B1 (de) 2010-04-21 2020-06-17 Syntarga B.V. Konjugate von cc-1065 analogen und bifunktionelle linker
EP3029066B1 (de) 2010-07-29 2019-02-20 Xencor, Inc. Antikörper mit modifizierten isoelektrischen punkten
WO2012045085A1 (en) 2010-10-01 2012-04-05 Oxford Biotherapeutics Ltd. Anti-rori antibodies
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
ES2640960T3 (es) 2011-06-28 2017-11-07 Oxford Biotherapeutics Ltd. Anticuerpos para ADP-ribosil ciclasa 2
CA2851534C (en) 2011-10-10 2023-02-14 Xencor, Inc. A method for purifying antibodies
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
JP2015502397A (ja) 2011-12-23 2015-01-22 ファイザー・インク 部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用
WO2014004549A2 (en) 2012-06-27 2014-01-03 Amgen Inc. Anti-mesothelin binding proteins
CA2891280C (en) 2012-11-24 2018-03-20 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
CN105051069B (zh) 2013-01-14 2019-12-10 Xencor股份有限公司 新型异二聚体蛋白
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
US9738722B2 (en) 2013-01-15 2017-08-22 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
EP3421495A3 (de) 2013-03-15 2019-05-15 Xencor, Inc. Modulation von t-zellen mit bispezifischen antikörpern und fc-fusionen
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
PL3587448T3 (pl) 2013-03-15 2021-11-29 Xencor, Inc. Białka heterodimeryczne
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
HRP20210410T1 (hr) 2013-10-11 2021-04-30 Oxford Bio Therapeutics Limited Konjugirana antitijela prema ly75 za liječenje raka
TR201810856T4 (tr) 2014-01-10 2018-08-27 Synthon Biopharmaceuticals Bv CYS'le bağlı antikor-ilaç konjugatlarını saflaştırmak için usul.
CN106414465B (zh) 2014-02-28 2021-11-16 杭州多禧生物科技有限公司 带电荷链接体及其在共轭反应上的应用
KR102497443B1 (ko) 2014-03-28 2023-02-08 젠코어 인코포레이티드 Cd38 및 cd3에 결합하는 이중특이적 항체
GB201406767D0 (en) 2014-04-15 2014-05-28 Cancer Rec Tech Ltd Humanized anti-Tn-MUC1 antibodies anf their conjugates
CA2956178A1 (en) 2014-07-24 2016-01-28 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
CA2967426A1 (en) 2014-11-26 2016-06-02 Xencor, Inc. Heterodimeric antibodies that bind cd3 and tumor antigens
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
BR112017011166A2 (pt) 2014-11-26 2018-02-27 Xencor, Inc. anticorpos heterodiméricos que se ligam a cd3 e cd38
EP3237449A2 (de) 2014-12-22 2017-11-01 Xencor, Inc. Trispezifische antikörper
WO2016141387A1 (en) 2015-03-05 2016-09-09 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
GB201506389D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
NZ739830A (en) 2015-07-12 2021-12-24 Hangzhou Dac Biotech Co Ltd Bridge linkers for conjugation of cell-binding molecules
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
CN108699136B (zh) 2015-12-07 2022-03-18 Xencor股份有限公司 结合cd3和psma的异二聚抗体
CA3026151A1 (en) 2016-06-14 2017-12-21 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
MX2018016265A (es) 2016-06-28 2019-07-04 Xencor Inc Anticuerpos heterodimericos que se unen al receptor 2 de somatostatina.
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
PE20240950A1 (es) 2016-10-14 2024-05-06 Xencor Inc PROTEINAS DE FUSION FC HETERODIMERICAS IL 15/IL 15R(alfa)
CN116143678A (zh) 2016-11-14 2023-05-23 杭州多禧生物科技有限公司 偶联连接体，含有此连接体的细胞结合分子-药物偶联物及其制备和应用
AU2018291497A1 (en) 2017-06-30 2020-01-16 Xencor, Inc. Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains
KR20200085828A (ko) 2017-11-08 2020-07-15 젠코어 인코포레이티드 신규의 항-pd-1 서열을 사용한 이중특이적 및 단일특이적 항체
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
EP3728302A1 (de) 2017-12-19 2020-10-28 Xencor, Inc. Modifizierte il-2-fc-fusionsproteine
EP3773911A2 (de) 2018-04-04 2021-02-17 Xencor, Inc. Heterodimere antikörper, die das fibroblastenaktivierungsprotein binden
MX2020010910A (es) 2018-04-18 2021-02-09 Xencor Inc Proteinas de fusion heterodimericas dirigidas a pd-1 que contienen proteinas de fusion il-15 / il-15ra fc y dominios de union al antigeno pd-1 y usos de los mismos.
KR20210003814A (ko) 2018-04-18 2021-01-12 젠코어 인코포레이티드 IL-15/IL-15Rα Fc-융합 단백질 및 TIM-3 항원 결합 도메인을 함유하는 TIM-3 표적화 이종이량체 융합 단백질
US11530274B2 (en) 2018-07-02 2022-12-20 Amgen Inc. Anti-STEAP1 antigen-binding protein
MX2021003765A (es) 2018-10-03 2021-07-15 Xencor Inc Proteínas il-12 de fusión a fc heterodimérico.
AU2020232605A1 (en) 2019-03-01 2021-10-21 Xencor, Inc. Heterodimeric antibodies that bind ENPP3 and CD3
US11919956B2 (en) 2020-05-14 2024-03-05 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
CA3212665A1 (en) 2021-03-09 2022-09-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cldn6
KR20230154311A (ko) 2021-03-10 2023-11-07 젠코어 인코포레이티드 Cd3 및 gpc3에 결합하는 이종이량체 항체
WO2022078524A2 (en) 2021-11-03 2022-04-21 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5084468A (en) * 1988-08-11 1992-01-28 Kyowa Hakko Kogyo Co., Ltd. Dc-88a derivatives
JP2510335B2 (ja) * 1989-07-03 1996-06-26 協和醗酵工業株式会社 Ｄｃ―８８ａ誘導体
KR910014122A (ko) * 1990-01-19 1991-08-31 디께다 가즈히꼬 에토포시드-2-디메틸아미노 화합물의 동결건조 제제
US5214065A (en) * 1990-06-11 1993-05-25 Kyowa Hakko Kogyo Co., Ltd. Dc-89 derivatives
JPH0669954B2 (ja) * 1990-12-07 1994-09-07 吉富製薬株式会社 抗腫瘍組成物
EP0499130A1 (de) * 1991-02-15 1992-08-19 Kyowa Hakko Kogyo Co., Ltd. Derivate der Verbindung DC-89
JP3608802B2 (ja) * 1991-09-20 2005-01-12 第一サントリーファーマ株式会社 安定なカルシトニン医薬組成物及びその製造法

Also Published As

Publication number Publication date
EP0754030A1 (de) 1997-01-22
BR9507640A (pt) 1997-08-19
HUT78072A (hu) 1999-08-30
WO1995031971A1 (en) 1995-11-30
US5703080A (en) 1997-12-30
FI964624A7 (fi) 1996-11-19
FI964624A0 (fi) 1996-11-19
NO964813D0 (no) 1996-11-13
SK148496A3 (en) 1997-06-04
DE69519667T2 (de) 2001-04-26
CZ338696A3 (en) 1997-05-14
FI964624L (fi) 1996-11-19
EP0754030B1 (de) 2000-12-20
NZ285450A (en) 1997-02-24
PL317229A1 (en) 1997-03-17
MX9605694A (es) 1998-05-31
JPH07309761A (ja) 1995-11-28
CN1148805A (zh) 1997-04-30
NO964813L (no) 1996-11-13
DE69519667D1 (de) 2001-01-25
HU9603521D0 (en) 1997-03-28
CA2190635A1 (en) 1995-11-30
AU2455195A (en) 1995-12-18

Similar Documents

Publication Publication Date Title
DE69519667D1 (de) Verfahren zur stabilisierung von duocarmycinderivaten
ATE260658T1 (de) Pharmazeutische zubereitungen zur verminderung von atmungsdepressionen
PL327169A1 (en) Naphtyl-substituted derivatives of benzimidazole as anticoagulants
PL292095A1 (en) Pesticides and method of obtaining them
KR950700894A (ko) 탁솔 유도체(Taxol derivatives)
ATE179976T1 (de) Neue 5-pyrrolyl-2-pyridylmethylsulfinyl benzimidazol-derivate
DE69221563D1 (de) Polyfluoralkylthiopoly(ethylimidazolium)-Verbindungen, Verfahren zu ihrer Herstellung und ihre Verwendung als biozide Mittel
AU699480B2 (en) 2,2-Dichloroalkane carboxylic acids, processes for their production and pharmaceutical agents containing these
KR960013370A (ko) 트리글리세리드 과다 방지 조성물
CA2119853A1 (fr) Nouvelles pyridothiadiazines, leurs procedes de preparation, et les compositions pharmaceutiques qui les contiennent
AU7700096A (en) Novel 2,3,5-trimethyl-4-hydroxyanilide derivatives, their preparation and their application in therapeutics
ATE247959T1 (de) Nicht peptidische g-csf mimetika
EP0340754A3 (de) Monopersulfate von Amino-(poly)percarbonsäuren
KR950700234A (ko) β-페닐이소세린 및 그외 동족체를 제조하는 방법(Method for preparing β-phenylisoserine and analogues thereof)
DE69330601D1 (de) Serotoninergische ergolin derivate
AU5644296A (en) Novel heterocyclic chemistry
ATE200482T1 (de) N-substituierte azabicycloheptan-derivate als neuroleptika usw.
BR9610175A (pt) Composto processo de preparação do composto composição farmacêutica e utilização do composto
ATE244224T1 (de) Verfahren zur umwandlung von 2,4-dichlorpyridinen in 2-aryloxy-4-chlorpyridine
DE3750267D1 (de) Herstellung von Piperidinylcyclopentylheptensäure-Derivaten.
HK1000859A (en) Method for stabilizing duocarmycin derivatives
SE9001592D0 (sv) A therapeutical composition
CA2142560A1 (fr) Nouveaux analogues de l'acronycine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
RU96124085A (ru) Способ стабилизации производных дуокармицина
KR910011258A (ko) 녹내장의 치료방법

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties